IP Library Granted Patent US 8,598,167
Granted Patent B1
US 8,598,167 · App. 13/938,067 · Granted Dec 3, 2013

Substituted 6,5-fused bicyclic heteroaryl compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,167
App. No.
13/938,067
Granted
Dec 3, 2013
Kind
B1
Abstract

The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Claims (18)

1. A compound of Formula (IIIa) or a pharmaceutically acceptable salt thereof:

wherein

each of R 1 , R 3 , R 8 , and R 11 is H;

each of R 2 and R 4 is methyl;

R 6 is phenyl or pyridinyl, each substituted with one -Q 2 -T 2 , in which Q 2 is a methyl linker and T 2 is morpholinyl, and R 6 is optionally further substituted with methyl or Cl; and

R 7 is cyclopentyl or isopropyl.

2. The compound of claim 1 , wherein R 6 is phenyl substituted with one -Q 2 -T 2 .

3. The compound of claim 1 , wherein R 6 is pyridinyl substituted with one -Q 2 -T 2 .

4. The compound of claim 2 , wherein R 7 is cyclopentyl.

5. The compound of claim 3 , wherein R 7 is cyclopentyl.

6. A compound selected from

and pharmaceutically acceptable salts thereof.

7. The compound

8. A pharmaceutically acceptable salt of

9. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising a compound of claim 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 8 and a pharmaceutically acceptable carrier.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2013
From: KUNTZ, KEVIN WAYNE; OLHAVA, EDWARD JAMES; CHESWORTH, RICHARD; DUNCAN, KENNETH WILLIAM
To: EPIZYME, INC.
Reel/Frame 031177/0001 →